Skip to main content

Featured

Markets Rebound as Hopes for Iran–U.S. Dialogue Ease Geopolitical Tensions

U.S. stock futures edged higher on Wednesday as signs of potential diplomatic movement in the Iran–U.S. standoff helped calm volatile markets. Futures tied to the S&P 500 rose about 0.3%, the Nasdaq 100 gained 0.5%, and Dow Jones Industrial Average futures added 0.2% after a turbulent prior session.  The shift in sentiment followed reports that Iran has quietly approached the United States to discuss terms for ending the escalating conflict , a development that helped cool fears of further disruption in global energy markets. This diplomatic signal contributed to a rebound after Tuesday’s sharp sell-off, when concerns over widening conflict and rising oil prices rattled investors.  The conflict, now in its fifth day, has seen continued strikes and mounting casualties, adding to market unease. Iran is preparing for the funeral of Supreme Leader Ali Khamenei, killed in recent attacks, while regional tensions remain high.  Despite the ongoing uncertainty, Wednesda...
Post a Comment
Read more

article

Labels

Alzheimer’s Drug Donanemab Receives FDA Advisers’ Endorsement for Slowing Disease Progression

 

A significant milestone has been reached in the fight against Alzheimer’s disease. Eli Lilly’s closely watched Alzheimer’s drug, donanemab, has won the unanimous backing of federal health advisers. The drug is specifically intended for people with mild dementia caused by this brain-robbing disease.

The decision by the Food and Drug Administration (FDA) advisers comes after careful consideration of the drug’s benefits and risks. Donanemab has demonstrated the ability to modestly slow cognitive decline and memory problems associated with Alzheimer’s. Although it’s not a cure, this endorsement represents a promising step forward in managing the disease.

Here are the key points:

  1. Effectiveness: Donanemab has shown effectiveness in slowing cognitive decline. Patients who received monthly intravenous infusions of the drug declined about 35% more slowly than those who received a placebo.
  2. Risk Assessment: The FDA panel weighed the risks, including side effects like brain swelling and bleeding, which will need monitoring. Despite these risks, the panel concluded that the drug’s benefits outweighed them.
  3. Tau Protein Screening: Unlike previous concerns about tau protein screening, most panelists believed there was enough evidence to prescribe the drug broadly without requiring such screening.
  4. FDA Decision: The FDA will make the final decision on approval later this year. If approved, donanemab would become only the second Alzheimer’s drug in the U.S. shown to convincingly slow cognitive decline.

This endorsement brings hope to individuals and families affected by Alzheimer’s, and we eagerly await the FDA’s final decision. Stay tuned for further updates on this groundbreaking development! 

Labels:

Comments

Post a Comment